CYMABAY THERAPEUTICS INC (CBAY)       8.82  +0.09 (+1.03%)

8.82  +0.09 (+1.03%)

US23257D1037 - Common Stock - After market: 8.82 0 (0%)

CYMABAY THERAPEUTICS INC8.82

NASDAQ:CBAY (3/28/2023, 7:14:51 PM)+0.09 (+1.03%)

After market: 8.82 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)03-16 2023-03-16/amc
Earnings (Next)05-10 2023-05-10/amc
Ins Owners0.18%
Inst Owners70.08%
Market Cap835.09M
Shares94.68M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts85.33
IPO01-16 2014-01-16

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CBAY Daily chart

Company Profile

CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. The company is headquartered in Newark California, California. The company went IPO on 2014-01-16. The firm is focused on developing and providing access to therapies for patients with liver and other chronic diseases. The firm's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation, and fibrosis. The company is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation. Its other product candidate, MBX-2982, targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.

Company Info

CYMABAY THERAPEUTICS INC

Suite 130, 7999 Gateway Blvd

Newark California CALIFORNIA 94560

P: 15102938800.0

CEO: Sujal Shah

Employees: 59

Website: https://www.cymabay.com/

CBAY News

News Image13 days ago - Seeking Alpha(NASDAQ:CBAY)

CymaBay Therapeutics press release (CBAY): Q4 GAAP EPS of -$0.30 misses by $0.01.Held $135.5 million in cash, cash equivalents and investments as of December 31, 2022.

News Image13 days ago - CymaBay Therapeutics, Inc.CymaBay Reports Fourth Quarter and Year Ended December 31, 2022 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30 p.m. ET...

News Image20 days ago - CymaBay Therapeutics, Inc.CymaBay Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023

NEWARK, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on...

News Image2 months ago - CymaBay Therapeutics, Inc.CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference

NEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on...

News Image2 months ago - CymaBay Therapeutics, Inc.CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

NEWARK, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on...

News Image2 months ago - Seeking AlphaCymaBay stock pops 7% after launching stock and warrants offering (NASDAQ:CBAY)

CymaBay Therapeutics (CYMA) on Monday announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants.

CBAY Twits

Here you can normally see the latest stock twits on CBAY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example